Clinically relevant drug-drug interactions in oncology

British Journal of Clinical Pharmacology

Volumn 45, Issue 6, 1998, Pages 539-544

  McLeod, Howard L ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cancer chemotherapy; Drug interactions; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALLOPURINOL; ANTICONVULSIVE AGENT; CARBOPLATIN; COUMARIN ANTICOAGULANT; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PHENOBARBITAL; PROBENECID; TENIPOSIDE; THYMIDYLATE SYNTHASE; VINCA ALKALOID;

CANCER CHEMOTHERAPY; COLORECTAL CANCER; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ONCOLOGY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG INTERACTIONS; HUMANS; METABOLIC CLEARANCE RATE;

EID: 0031865665     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00719.x     Document Type: Review

References (33)

1. McLeod HL. Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol Ther 1997; 74: 39-54.
2. Calvert AH. Dose optimization of carboplatin in adults. Anticancer Res 1994; 14: 2273-2277.
3. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12: 1667-1672.
4. van Meerten E, Verweij J, Schellens JHM. Antineoplastic agents: Drug interactions of clinical significance. Drug Safety 1995; 12: 168-182.
5. Lennard L. The clinical pharmacology of 6-niercaptopunne. Eur Clin Pharmacol 1992; 43: 329-339.
6. Poplack DG, Balis FM, Zimm S. The pharmacology of orally administered chemotherapy. A reappraisal. Cancer 1986; 58: 473-480.
7. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: The pnce of an avoidable drug-interaction. Ann Pharmacother 1996; 30: 951-954.
8. Balis FM, Holcenberg JS, Zimm S, et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 1987; 41: 384-387.
9. Innocenti F, Danesi R, Dipaolo A, et al. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharmacol 1996; 37: 409-414.
10. Riva R, Albani F, Contin M, Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs - Clinical considerations. Clin Pharmacokin 1996; 31: 470-493.
11. Baker DK, Relling MV, Pui CH, et al. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992; 10: 311-315.
12. Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12: 2390-2397.
13. Grem JL, Chu E, Boarman D, et al. Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations. Semin Oncol 1992; 19, S3: 36-14.
14. Seymour MT, Patel N, Johnston A, Joel SP, Slevin ML. Lack of effect of interferon alpha-2A upon fluorouracil pharmacokinetics. Br J Cancer 1994; 70: 724-728.
15. Swinbanks D. Deaths bring clinical trials under scrutiny in Japan. Nature 1994; 369: 697.
16. Watabe T. Strategic proposals for predicting drug-drug interactions during new drug development: Based on sixteen deaths caused by interactions of the new antiviral sorivudine with fluorouracil prodrugs. J Toxicol Sci 1996; 21: 299-300.
17. Brown MC. Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil. Pharmacotherapy 1997; 17: 631-633.
18. Aherne GW, Piall E, Marks V, et al. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J 1978; 1: 1097-1099.
19. Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low-dose methotrexate and probenecid. J Rheumat 1991; 18: 609-610.
20. Machover D. A comprehensive review of 5-fluorouracil and leucovonn in patients with metastatic colorectal carcinoma. Cancer 1997; 80: 1179-1187.
21. Baker SD. Drug interactions with the taxanes. Pharmacotherapy 1997; 17: S126-S32.
22. Calvert AH. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin Oncol 1997; 24, S2: S85-S90.
23. Kearns CM, Egorin MJ. Considerations regarding the less than expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 1997; 24, S2: S91-S96.
24. Schellens JHM, MaJ, Bruno R, et al. Pharmacokinetics of cisplatin and taxotere (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence taxotere/cisplatin and cisplatin/taxotere in a phase I/II study in solid tumor patients. Proc Am Soc Clin Oncol 1994; 13: 132.
25. McLeod HL. Clinical reversal of the multidrug resistance phenotype: True tumor modulation or pharmacokinetic interaction. Eur J Cancer 1994; 30A: 2039-2041.
26. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-1642.
27. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450, 3A4 and an unknown P450 enzyme. Cancer Res 1994;; 54: 4026-4035.
28. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6-alpha-hydroxytaxol by human cytochrome P450, 2C8. Cancer Res 1994;; 54: 5543-5546.
29. Crespi CL, Penman BW, Gonzalez FJ, Gelboin HV, Galvin M, Langenbach R. Genetic toxicology using human cell lines expressing human P-450. Biochem Soc Trans 1993; 21: 1023-1028.
30. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochrome P450, 2B and cytochrome; P450, 3A: in human liver microsomes. Cancer Res 1993; 53: 5629-5637.
31. Jones TE. The use of other drugs to allow a lower dosage of cyclosporin to be used - Therapeutic and pharmacoeconomic considerations. Clin Pharmacokinet 1997; 32: 357-367.
32. Sobh M, Elagroudy A, Moustafa F, Harras F, Elbedewy M, Ghoneim M. Coadministration of ketoconazole to cyclosporine treated kidney transplant recipients: A prospective randomized study. Am J Nephrol 1995; 15: 493-499.
33. Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine cyclosporine prednisolone, a novel immunosuppressive regimen. Lancet 1993; 342: 83-84.